Blog

Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers

Photo of Denis Wirtz from Johns Hopkins Whiting School of Engineering

Jul 30, 2024, 13:29

Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers

Denis Wirtz, Vice Provost of Research at Johns Hopkins University, shared on X about recent paper by Paul M. Kuhn et al., titled “Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer” published on MDPI.

Authors: Paul M. Kuhn, Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz and Efrosini Kokkoli

“MEK inhibitors have significant off-target toxicity and lack predictive biomarkers.

Here, we use a thermosensitive, biodegradable hydrogel with functionalized liposomes for sustained release of MEK inhibitors to E-cad-positive breast tumors.”

Source: Denis Wirtz/X

Aditya Venkatraman Ashleigh J. Crawford Bartholomew A. Starich Breast Cancer cancer Denis Wirtz Efrosini Kokkoli Gabriella C. Russo Johns Hopkins University MEK inhibitors Nanlan Yang OncoDaily Oncology Paul M. Kuhn Pei-Hsun Wu Thi Vo Zachary Schneiderman

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity